- Home
- ZI vs DNLI Comparison
ZI vs DNLI Comparison
Compare ZI & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZI
- DNLI
- Stock Information
- Founded
- ZI 2007
- DNLI 2013
- Country
- ZI United States
- DNLI United States
- Employees
- ZI N/A
- DNLI N/A
- Industry
- ZI Computer Software: Prepackaged Software
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZI Technology
- DNLI Health Care
- Exchange
- ZI Nasdaq
- DNLI Nasdaq
- Market Cap
- ZI 3.5B
- DNLI 3.1B
- IPO Year
- ZI 2020
- DNLI 2017
- Fundamental
- Price
- ZI $9.65
- DNLI $20.73
- Analyst Decision
- ZI Hold
- DNLI Strong Buy
- Analyst Count
- ZI 20
- DNLI 13
- Target Price
- ZI $12.05
- DNLI $37.91
- AVG Volume (30 Days)
- ZI 4.9M
- DNLI 814.8K
- Earning Date
- ZI 02-25-2025
- DNLI 03-04-2025
- Dividend Yield
- ZI N/A
- DNLI N/A
- EPS Growth
- ZI N/A
- DNLI N/A
- EPS
- ZI 0.02
- DNLI N/A
- Revenue
- ZI $1,221,600,000.00
- DNLI N/A
- Revenue This Year
- ZI N/A
- DNLI N/A
- Revenue Next Year
- ZI N/A
- DNLI $289.18
- P/E Ratio
- ZI $399.90
- DNLI N/A
- Revenue Growth
- ZI N/A
- DNLI 204.74
- 52 Week Low
- ZI $7.65
- DNLI $14.56
- 52 Week High
- ZI $17.70
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- ZI 39.14
- DNLI 42.56
- Support Level
- ZI $9.98
- DNLI $21.33
- Resistance Level
- ZI $10.64
- DNLI $22.81
- Average True Range (ATR)
- ZI 0.34
- DNLI 1.27
- MACD
- ZI -0.04
- DNLI -0.10
- Stochastic Oscillator
- ZI 1.98
- DNLI 15.83
About ZI ZoomInfo Technologies Inc
ZoomInfo Technologies Inc provides a go-to-market intelligence platform for sales and marketing teams. Its cloud-based go-to-market data and insights platform deliver comprehensive and high-quality intelligence and analytics to provide sales and marketing professionals with accurate information and insights on the organizations and professionals. Nearly all of its revenue is derived from the United States.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.